{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:26:41Z","timestamp":1791052001187,"version":"4.1.0"},"reference-count":52,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antiviral Therapy"],"published-print":{"date-parts":[[2009,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The aim of this study was to assess the effect of insulin resistance (IR) on the response to hepatitis C virus (HCV) therapy in HIV-HCV-coinfected patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 238 HIV-HCV-coinfected patients (74% male, mean \u00b1sd age 40 \u00b15 years, mean alcohol intake &lt;50 g\/day and 38% HCV genotype 2 or 3), treated by standard or pegylated interferon-\u03b12b plus ribavirin during 48 weeks were studied. Liver biopsies were assessed before treatment. Patients were considered to have IR when the homeostasis model assessment of IR (HOMA-IR) was \u22652.5. Multiple logistic regression with stepwise selection was used to estimate independent factors associated with sustained virological response (SVR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>IR was present in 32% and significant liver fibrosis (Metavir\u2265F2) in 74% of patients. Patients with SVR (96\/238 [40%]) were more likely to be infected with HCV genotype 2 or 3 (54% versus 27%; P&lt;0.0001), and had more severe liver fibrosis (\u2265F3; 45% versus 30%; P=0.03). By multivariate analysis, a HOMA-IR&gt;2.5 had a negative effect on the SVR (odds ratio 0.49 [95% confdence interval 0.26-0.92]; P=0.05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A high HOMA-IR level is frequently found in HIV-HCV-coinfected patients and is associated with a reduced SVR rate. Improving insulin sensitivity might be a useful adjunct to HCV therapy in HIV-HCV-coinfected patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3851\/imp1298","type":"journal-article","created":{"date-parts":[[2009,10,5]],"date-time":"2009-10-05T13:58:45Z","timestamp":1254751125000},"page":"839-845","source":"Crossref","is-referenced-by-count":25,"title":["Insulin resistance impairs sustained virological response rate to pegylated interferon plus ribavirin in HIV\u2013hepatitis C virus-coinfected patients: HOMAVIC-ANRS HC02 Study"],"prefix":"10.1177","volume":"14","author":[{"given":"Patrice","family":"Cacoub","sequence":"first","affiliation":[{"name":"Universit\u00e9 Pierre et Marie Curie-Paris 6, CNRS, UMR 7087, Paris, France"},{"name":"AP-HP, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, Service de M\u00e9decine Interne, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Carrat","sequence":"additional","affiliation":[{"name":"UMR-S707, Public-Health Unit, Universit\u00e9 Paris 6, Paris, France"},{"name":"GHU-Est, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"B\u00e9dossa","sequence":"additional","affiliation":[{"name":"Service d'Anatomopathologie, H\u00f4pital Beaujon, Clichy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Lambert","sequence":"additional","affiliation":[{"name":"UMR-S707, Public-Health Unit, Universit\u00e9 Paris 6, Paris, France"},{"name":"GHU-Est, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"P\u00e9naranda","sequence":"additional","affiliation":[{"name":"Laboratoire Alphabio-CDL Pharma, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislas","family":"Pol","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9patologie, H\u00f4pital Cochin, Universit\u00e9 Ren\u00e9 Descartes Paris V, Paris, France"},{"name":"INSERM U 567, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Halfon","sequence":"additional","affiliation":[{"name":"Laboratoire Alphabio-CDL Pharma, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2009,8,1]]},"reference":[{"key":"bibr1-IMP1298","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20983"},{"key":"bibr2-IMP1298","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.02.035"},{"key":"bibr3-IMP1298","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.30983"},{"key":"bibr4-IMP1298","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.12.049"},{"key":"bibr5-IMP1298","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21455"},{"key":"bibr6-IMP1298","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-138-3-200302040-00012"},{"key":"bibr7-IMP1298","first-page":"64","volume":"5","author":"Sherman K.","year":"2000","journal-title":"Antivir Ther"},{"key":"bibr8-IMP1298","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510300409"},{"key":"bibr9-IMP1298","doi-asserted-by":"publisher","DOI":"10.1086\/317644"},{"key":"bibr10-IMP1298","doi-asserted-by":"publisher","DOI":"10.1016\/S1665-2681(19)32152-0"},{"key":"bibr11-IMP1298","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.40670.x"},{"key":"bibr12-IMP1298","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.26517"},{"key":"bibr13-IMP1298","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200301010-00005"},{"key":"bibr14-IMP1298","doi-asserted-by":"publisher","DOI":"10.1089\/08892220152644160"},{"key":"bibr15-IMP1298","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200007010-00003"},{"key":"bibr16-IMP1298","doi-asserted-by":"publisher","DOI":"10.1086\/380130"},{"key":"bibr17-IMP1298","doi-asserted-by":"publisher","DOI":"10.1086\/319747"},{"key":"bibr18-IMP1298","doi-asserted-by":"publisher","DOI":"10.1086\/318501"},{"key":"bibr19-IMP1298","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200204010-00009"},{"key":"bibr20-IMP1298","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200308150-00009"},{"key":"bibr21-IMP1298","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2006.00791.x"},{"key":"bibr22-IMP1298","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032653"},{"key":"bibr23-IMP1298","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040842"},{"key":"bibr24-IMP1298","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.23.2839"},{"key":"bibr25-IMP1298","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200409030-00003"},{"key":"bibr26-IMP1298","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840200104"},{"key":"bibr27-IMP1298","doi-asserted-by":"publisher","DOI":"10.1007\/BF00280883"},{"key":"bibr28-IMP1298","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2007.48.2.274"},{"key":"bibr29-IMP1298","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjhyper.2004.09.011"},{"key":"bibr30-IMP1298","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06102-5"},{"key":"bibr31-IMP1298","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32826fb710"},{"key":"bibr32-IMP1298","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2006.11.002"},{"key":"bibr33-IMP1298","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.12.017"},{"key":"bibr34-IMP1298","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(05)00706-8"},{"key":"bibr35-IMP1298","unstructured":"Ryan P., Resino S., Miralles P. Insulin resistance impairs sustained virologic response to interferon plus ribavirin in HIV\/HCV co-infected patients.\n                      16th Conference on Retroviruses and Opportunistic Infections\n                      . 8\u201311 February 2009, Montreal, QC, Canada. Abstract Q-162."},{"key":"bibr36-IMP1298","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.10.032"},{"key":"bibr37-IMP1298","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282fbd1c4"},{"key":"bibr38-IMP1298","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318186ede8"},{"key":"bibr39-IMP1298","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21429"},{"key":"bibr40-IMP1298","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.30692"},{"key":"bibr41-IMP1298","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.11.010"},{"key":"bibr42-IMP1298","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2007.07.026"},{"key":"bibr43-IMP1298","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000210606.63138.f5"},{"key":"bibr44-IMP1298","unstructured":"Mira J.A., Torre-Cisneros J., Merino D. Efficacy of pegylated intereron plus ribavirin in HIV\/HCV coinfection outside of well circumscribed clinical trials: the Andalusian multicenter study.\n                      13th Conference on Retroviruses and Opportunistic Infections\n                      , 5\u20138 February 2006, Denver, CO, USA. Abstract 861."},{"key":"bibr45-IMP1298","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.41403.x"},{"key":"bibr46-IMP1298","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.01.003"},{"key":"bibr47-IMP1298","unstructured":"Shire N., Rao M., Andersen J. Improving non-invasive discrimination of fibrosis in HIV\/HCV-co-infected patients.\n                      14th Conference on Retroviruses and Opportunistic Infections.\n                      25\u201328 February 2007, Los Angeles, CA, USA. Abstract 914."},{"key":"bibr48-IMP1298","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.03.033"},{"key":"bibr49-IMP1298","doi-asserted-by":"publisher","DOI":"10.2337\/db07-0827"},{"key":"bibr50-IMP1298","doi-asserted-by":"publisher","DOI":"10.1126\/science.1120781"},{"key":"bibr51-IMP1298","doi-asserted-by":"crossref","first-page":"383A","DOI":"10.1016\/j.jhep.2007.12.006","volume":"48","author":"Elgouhari H.M.","year":"2008","journal-title":"Hepatology"},{"key":"bibr52-IMP1298","doi-asserted-by":"crossref","first-page":"380A","DOI":"10.1016\/j.jhep.2007.11.007","volume":"48","author":"Romero Gomez M.","year":"2008","journal-title":"Hepatology"}],"container-title":["Antiviral Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP1298","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP1298","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:49:06Z","timestamp":1777380546000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3851\/IMP1298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["10.3851\/IMP1298"],"URL":"https:\/\/doi.org\/10.3851\/imp1298","relation":{},"ISSN":["1359-6535","2040-2058"],"issn-type":[{"value":"1359-6535","type":"print"},{"value":"2040-2058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}